Contact this trialFirst, we need to learn more about you.
Glucagon Receptor Agonist
Dasiglucagon for Congenital Hyperinsulinism
Recruiting2 awardsPhase 3
Philadelphia, Pennsylvania
This trial is for children with Congenital Hyperinsulinism who have completed either ZP4207-17103 or ZP4207-17109. The objective is to evaluate the long-term safety of dasiglucagon administered as a subcutaneous infusion.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.